Trial of Multi-Strain Probiotic Supplementation (Hexbio®) in Malaysian Patients With Drug-Resistant Epilepsy (ProbE)

NAActive, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2026

Conditions
Epilepsies Refractory
Interventions
DIETARY_SUPPLEMENT

Probiotic Agent

HEXBIO MCP Granule probiotic is prepared in sachets which consist of the following probiotics: Lactobacillus acidophilus (BCMC 1 12130)107mg, Lactobacillus casei (BCMC 1 12313) -107mg, Lactobacillus lactis (BCMC 1 12451)-107 mg, (BCMC 1 02290) -107mg, Bifidobacterium infantis (BCMC 1 02129) -107mg and Bifidobacterium longum (BCMC 102120)-107mg

DIETARY_SUPPLEMENT

Placebo

The placebo sachets will contain the same ingredient as the probiotic sachet but without the Lactobacillus sp. and Bifidobacterium sp. Participants in the placebo group will receive an identical Hexbio sachet (aluminum foil sachet.) with non-microbial material.

Trial Locations (1)

56000

National University of Malaysia, Kuala Lumpur

All Listed Sponsors
collaborator

B-Crobes Laboratory Sdn. Bhd

UNKNOWN

lead

National University of Malaysia

OTHER